Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zila divertiture approved

This article was originally published in The Tan Sheet

Executive Summary

Zila receives shareholder approval to divest wholly-owned subsidiary Zila Nutraceuticals to NBTY, the Phoenix-based firm announces Sept. 28. The company expects the divestiture to be completed Oct. 2 for $37.5 mil. in a total cash transaction with up to an additional $3 mil. to be paid through an "earn-out formula dependent upon the future performance of the business." NBTY in August announced the proposed acquisition of the nutraceutical division, which includes the Ester-C and Ester-E branded ingredients (1"The Tan Sheet," Aug. 21, 2006, p. 5)...

You may also be interested in...

NBTY Expands Into Mass Market With Zila Acquisition

NBTY is looking to use Ester-C brand recognition and loyalty to gain traction in the mass retail market

Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity

Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.

Lilly’s 340B Restrictions: Jury Is Still Out On Appropriateness, But Optics Are Bad, HHS Says

Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts